Page results
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
Sarcoma treatment is often extensive and can impact on a person’s ability to continue in work or return to work. While some people can continue working throughout their cancer treatment, others…
-
The first UK participant in a portion of a study looking at a new investigational medication for Covid-19 has received their initial dose of the drug at UCLH.
-
A new research study at UCLH and UCL will investigate how a rare type of blood cancer develops and what types of treatment may be effective for patients.
-
Achilles Therapeutics, a company built on research at UCLH, UCL Cancer Institute and the Francis Crick Institute has successfully raised $175.5 million through its initial public offering in the United States.
-
We are excited to announce that we have some new additions to the team. Welcome to Melissa Millson and Emilia (Millie) Jewitt, who have joined the nursing team and to Charlotte Yarnton, who has…
-
It is with great pleasure and excitement that we share with you news of an excellent new resource that can be used across the UK for people living with Sickle Cell Disorder.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Could dogs offer quick and effective diagnosis of COVID-19?
File results
-
Council of Governors meeting papers - 31 October
-
Consultant - to -consultant referral form
-
UCLH Provider to Provider Tariff 2019-20
-
What young people would like everyone to know about Type 1 Diabetes
-
Reverse mentoring
-
FOI/2020/0572 - Inflamatory bowel disease staff contact details
-
FOI2017294 Contactors and subcontractors working on the Phase 4 and proton therapy beam
-
FOI/2020/0589 - Senior staff contacts for CEO, Director of Innovation and Chief Pharmacist
-
FOI/2020/0630 - CEO, Operations Director and Health and Safety Director contact details
-
FOI2017333 Midwifery contacts for accessing return to practice placements